Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
FDA Recalls Over 3 Million Eye‑Drop Bottles Over Sterility Concerns
The U.S. Food and Drug Administration has issued a recall of more than 3 million eye‑drop bottles after sterility concerns were identified. The products, manufactured by K.C. Pharmaceuticals in Pomona, California, span eight categories and are sold under a wide range of store‑brand names at major retailers. No serious illnesses have been linked to the current recall, but the move revives memories of a 2023 eye‑drop outbreak that caused deaths and vision loss.
University of Arizona Launches $12 Million Rapamycin Clinical Trial
The University of Arizona’s R. Ken Coit College of Pharmacy is launching a double‑blind, randomized Phase 3 clinical trial to test low‑dose rapamycin’s ability to boost resilience and immune function in adults aged 65 and older. The six‑year study, funded by a $12 million...
HexemBio Raises $10.4M for a Stem Cell Rejuvenation Therapy
HexemBio announced a $10.4 million seed round led by Draper Associates to develop a blood‑stem‑cell rejuvenation therapy built on its Synthetic Human Yolk Sac platform. The technology temporarily places a patient’s own haematopoietic cells into a recreated embryonic niche, then returns...
Trump's $73B GovTech Budget Cuts Target NIH, NSF and Security Programs
President Donald Trump unveiled a FY2027 discretionary budget that trims $73 billion from domestic programs, including a $5 billion reduction to the National Institutes of Health and a 55% cut to the National Science Foundation. The plan reshapes federal research, health tech...
Untitled
Medline (Nasdaq: MDLN) has launched Pick Pack Pro™, an automated fulfillment system at its Montgomery, N.Y., distribution center. The technology combines robotics, conveyor sortation and right‑size packaging to handle high‑volume, narrow‑catalog orders for health plan members. By optimizing order batching...
Deal Roundup: EQT Life Sciences Exits Tubulis to Gilead, Foresight Scores 4x Return Selling TES to Legrand
EQT Life Sciences has exited its minority stake in Tubulis, the German clinical‑stage biotech developing next‑generation antibody‑drug conjugates, selling the position to Gilead Sciences. The transaction adds a promising ADC platform to Gilead’s oncology portfolio. In a separate deal, private‑equity...
The Future of Cell & Gene Therapy: Key Trends to Watch
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
From Low Yields to High Efficiency: Modernizing Complex Biologics Manufacturing
WuXi Biologics hosted a webcast detailing an integrated platform that can boost yields of complex biologics up to six‑fold while cutting manufacturing costs by as much as 80%. The approach combines platform‑based media optimization, cell‑culture intensification via WuXiUI™, downstream capacity...
From PC to CPV: Preserving Process Knowledge Through Late‑Phase Tech Transfer
Catalent’s Danielle Wittenwyler, PhD, will host a webinar on preserving years of process characterization (PC) during late‑phase tech transfers. She outlines a structured, risk‑based methodology that translates sponsor‑generated PC into Catalent’s Madison facility while maintaining design‑space intent. The approach identifies...
Beyond Physician Burnout and Understanding Structural Immiseration
Patrick Hudson argues that labeling physician distress as "burnout" obscures the deeper, systemic forces eroding doctors' sense of purpose. He introduces "structural immiseration" to describe how electronic health records, metric‑driven workflows, and administrative demands strip clinicians of autonomy and authorship....
Cell‑Replacement Trials Edge Closer to Type 1 Diabetes Cure, Researchers Say
Late‑stage cell‑replacement trials are expected to read out within the next few years, bringing a functional cure for type 1 diabetes into view. Researchers cite stem‑cell transplants and immune‑shielding strategies as the next frontier, while patients and advocates stress the life‑changing...
The Role of Class of Trade Research in Pharmaceutical Market Access
Manasi Salgaonkar highlights that class of trade (CoT) research is essential for precise pharmaceutical pricing, contract eligibility, and regulatory compliance. Accurate CoT classification links dispensing settings—retail, hospital, specialty, mail‑order, and IDNs—to specific pricing tiers and rebate agreements. Continuous updates are...
Stipple Launches with $100M for Novel Oncology Targets
Stipple, a new biotech focused on oncology, announced a $100 million Series A financing round to pursue novel, historically undruggable cancer targets. The round was led by top‑tier venture firms and includes strategic commitments from several large pharmaceutical partners. Stipple’s founding team...
Optimization of Brain-Permeable SGK1 Inhibitors for Neurodegenerative Diseases
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that alleviate inflammatory and neuropathic pain in rodent studies and are slated for IND‑enabling toxicology this year, aiming for Phase I trials in 2027. Parallel research highlights chronic inflammation’s role...
Dectisomes Show Potent Activity Against High-Priority Fungal Pathogens
Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that show potent analgesic effects with minimal off‑target activity. New research links chronic inflammation in the bone‑marrow niche to epigenetic reprogramming of hematopoietic stem cells, suggesting early‑intervention strategies for leukemia prevention. Infinimmune...
Suzhou Spring-Sea Bio-Pharmaceuticals Identifies New GLP-1R Agonists
Suzhou Spring‑Sea Bio‑Pharmaceuticals announced the discovery of a novel series of glucagon‑like peptide‑1 receptor (GLP‑1R) agonists that demonstrate high potency and prolonged half‑life in pre‑clinical models. The compounds show superior glucose‑lowering efficacy compared with existing market leaders and exhibit favorable...
Acadia Pharmaceuticals Presents GPR88 Agonists
Researchers at Jiangsu and Shanghai Hengrui have patented Nav1.8 blockers that deliver strong analgesic effects while sparing off‑target channels, opening a new avenue for chronic pain therapy. Parallel studies reveal that chronic inflammation can reprogram hematopoietic stem cells, driving early...
Orexin OX2 Receptor Agonists Disclosed in Vertex Pharmaceuticals Patent
Vertex Pharmaceuticals has filed a patent covering a new series of orexin OX2‑receptor agonists, marking the company’s first public foray into sleep‑modulating therapeutics. The disclosed molecules feature distinct heterocyclic cores and enhanced blood‑brain barrier penetration, aiming for improved potency and...
Holiday Notice
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that demonstrate potent analgesic effects with minimal off‑target activity, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes the bone‑marrow microenvironment, driving hematopoietic...
Chengdu Kanghong Pharmaceutical Patents New Lipoprotein(a)-Lowering Agents
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that relieve neuropathic and inflammatory pain in rodents without impairing motor function, with filings in China and the United States and IND‑enabling work slated for later this year....
Next-Generation Anti-CD30 ADC Outperforms Brentuximab Vedotin
Biopharma X unveiled a next‑generation anti‑CD30 antibody‑drug conjugate that demonstrated superior efficacy and tolerability compared with the established therapy brentuximab vedotin. In preclinical models, the ADC achieved deeper tumor regressions and a broader therapeutic window, driven by an optimized linker...
Nrf2 Activator Counteracts Atopic Dermatitis Pathology
Researchers have identified a novel Nrf2 activator that mitigates key pathological features of atopic dermatitis in preclinical studies. The compound suppresses oxidative stress and downregulates pro‑inflammatory cytokines, leading to restored skin barrier integrity in murine models. Data presented at the...
New LRH-1 Antagonists Exhibit Antitumor Activity in Prostate Cancer Models
Researchers have identified a new class of liver receptor homolog‑1 (LRH‑1) antagonists that demonstrate potent antitumor activity in preclinical prostate cancer models. In mouse xenografts, oral administration of the compounds reduced tumor volume by up to 65% without notable adverse...
Emory University Synthesizes New Prostaglandin EP2 Receptor Antagonists
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver potent analgesic effects with minimal off‑target activity, opening a new avenue for chronic pain therapy. Parallel studies highlight how chronic inflammatory signals remodel hematopoietic stem cells,...
Boehringer Ingelheim’s Confident New Leap in the Obesity Market
Boehringer Ingelheim has created a new obesity and liver health unit led by senior vice president Vani Manja, targeting a rapidly expanding GLP‑1 market that could reach 25 million U.S. patients by 2030. The company’s pipeline features the dual glucagon/GLP‑1 agonist...
Ventricular Septal Rupture: The Echo That Changes Everything
Ventricular septal rupture (VSR) is a rare but life‑threatening complication that sonographers may encounter only a few times in their careers. The article explains how VSR forms, why the defect’s location influences treatment, and which echocardiographic signs signal its presence....
Higher Protein Intake Reverses Sarcopenia in Elderly Women
As a medical school professor, the protein recommendation I was taught -- 0.8 g/kg body weight -- is actively harming older adults. New data proves it. A 2025 Frontiers in Nutrition trial randomized 126 elderly women with sarcopenia into two groups...
University of Arizona Launches $12 Million Rapamycin Clinical Trial
University of Arizona’s R. Ken Coit College of Pharmacy is launching a double‑blind, randomized Phase 3 clinical trial to test low‑dose rapamycin’s ability to improve resilience and immune function in adults 65 and older. The $12 million study is fully funded by...
Re: The United States Is Driving a Public Health Emergency of International Concern
A trio of European epidemiologists reaffirmed that the United States’ 2024 withdrawal from the World Health Organization satisfies the International Health Regulations’ criteria for a Public Health Emergency of International Concern (PHEIC). They cite their February 2025 LinkedIn analysis, which...
Sanofi Immune Drug Hopeful Posts Mixed Results in Mid-Stage Tests
Sanofi reported mixed Phase 2 results for its bispecific antibody lunsekig. The drug achieved its primary and key secondary endpoints in moderate‑to‑severe asthma and chronic rhinitis with nasal polyps, showing reduced exacerbations, improved lung function and smaller polyps. Conversely, lunsekig failed...
Biogen Collaborates with Alloy Therapeutics to Advance Antisense Therapeutics
Biogen has signed a collaboration and license agreement with Alloy Therapeutics to use the company’s AntiClastic antisense oligonucleotide (ASO) platform on multiple undisclosed targets. The deal provides Alloy with an upfront cash payment, additional milestone fees and tiered royalties on...
Patient Spreads Word About Hospice En Route to the Stars
Pam Harter, a hospice patient in Napa, California, is campaigning to become the first hospice patient in space while using her journey to highlight the benefits of hospice care. Diagnosed with the rare genetic disorder pseudoxanthoma elasticum, she entered hospice...
NHS Preps Major Tech Programme to ‘Transform Patient, Public and Staff-Facing Services’
On 1 April, NHS England launched the TPPSFS programme, a £250 million (£320 million) initiative that subsumes the existing Digital Transformation of Screening project and aims to overhaul patient, public and staff‑facing services. The plan outlines eight priority areas, including a full...
Gilead to Buy Germany’s Tubulis for up to $5 Billion to Boost Cancer Pipeline
Gilead Sciences announced it will acquire Germany‑based Tubulis GmbH for up to $5 billion, adding the biotech’s antibody‑drug conjugate (ADC) platform to its portfolio. The deal follows Gilead’s recent $7.8 billion purchase of Arcellx and a $2 billion acquisition of Ouro Medicines, reflecting...
Gilead Continues Dealmaking Streak with $3.15B Tubulis Buy for ADCs
Gilead announced its third acquisition of 2026, agreeing to pay $3.15 billion upfront for Tubulis, a German startup that has built a next‑generation antibody‑drug conjugate (ADC) platform. The deal includes a contingent earn‑out of up to $1.85 billion tied to future milestones....
Kry Livi and HA | Wisdom Wellbeing Partner to Bring Digital GP Access to Thousands of Individuals
Kry Livi has teamed up with HA | Wisdom Wellbeing to embed its fast‑access digital GP service into the provider’s Employee Assistance Programme, extending coverage to more than 16 million people across the UK and Ireland and over 90,000 organisations. Users...
Exercise Cuts Visceral Fat, Boosts Insulin Sensitivity in NIDDM
Mobilization of Visceral Adipose Tissue Related to the Improvement in Insulin Sensitivity in Response to Physical Training in NIDDM: Effects of branched-chain amino acid supplements 🔘"Patients who exercised increased their VO2 peak by 41% and their insulin sensitivity by 46%... 🔘with a...
Sarcopenia Doubles Death and Disability Risk in Seniors
As a medical school professor, I can tell you the most dangerous disease you have never heard of is sarcopenia -- and a massive new meta-analysis just proved it. A 2026 Frontiers in Nutrition review of thousands of community-dwelling older adults...
AI Sleep Apnea Detection Tool Draws 150,000 Pre-Launch Sign-Ups
Sleep Cycle, the AI‑powered sleep‑tracking app, announced that more than 150,000 users have pre‑registered for its upcoming AI‑driven sleep apnea risk detection tool. The sign‑ups, mainly from the United States and United Kingdom, skew toward adults over 45, a group...
Tech Revolution Will Redefine Some Medical Specialties More Than Others
Every medical specialty will transform differently due to the technological revolution. In certain fields, such as nursing, psychiatry, obstetrics and gynecology, innovation will have much less impact than on dentistry, cardiology or pathology. In this e-book, we specify in detail how...
Trump's 100% Pharma Tariffs Threaten U.S. Drug Prices
Spent last year deep in supply chain security for my book—pharma near the top of the list for policymakers globally. Excited to dig into Trump's latest tariff announcement with @TomBollyky, one of the leading voices on trade, security, and public...
A Smaller Social Network Increases Loneliness More Drastically for Those with Depression
A cross‑sectional study of 4,042 German adults found that fewer daily social contacts are linked to higher loneliness, a relationship that holds for both healthy and depressed participants. The association is markedly stronger among the 1,221 respondents with a lifetime...
CEO Kazimi Explores Computation, Chemistry, Culture in Drug Discovery
Computation, Chemistry & Culture for Drug Discovery: Nimbus Therapeutics CEO Abbas Kazimi is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/XCysW6El1o
X7 Humanoid Robot Streamlines Hospital Medication Dispensing
Meet X7: The Humanoid #Robot Helping Dispense Medicines in Hospitals by @CyberRobooo #Robotics #MachineLearning #ArtificialIntelligence #Innovation #Technology #AI #ML https://t.co/XwQfzq5NNf
Telehealth Now Accounts for 43% of Medicare Mental Health Visits, JAMA Network Open Study Finds
A JAMA Network Open study of 9.6 million Medicare fee‑for‑service beneficiaries shows telehealth now accounts for 42.9% of outpatient mental‑health visits, up from 2.1% before COVID‑19. The surge peaked at 54.4% during the acute pandemic and settled at a stable post‑pandemic...
Four‑Month MDF Cuts NAFLD Liver Fat by 24%
"The 4-month intervention with this MDF was effective in reducing IHTC in patients with NAFLD by an absolute reduction of −5.89% and a relative reduction of −24.30% after adjusting for weight loss. Such effect was partly mediated by altered composition...
California Man Pleads Guilty to Orchestrating $270M Medication Reimbursement Fraud Scheme
A California man pleaded guilty to submitting nearly $270 million in fraudulent Medi‑Cal claims over an 11‑month period, billing the state for expensive prescription drugs that were either unnecessary or never dispensed. The scheme leveraged a temporary suspension of prior‑authorization requirements,...
Evommune Bucked Biotech IPO Drought and Is Focused on the Long Game
Evommune became one of only eleven biotech companies to go public in 2025, breaking a severe IPO drought that followed the 2021 funding boom. The firm’s phase 2a trial of its IL‑18 biologic EVO301 showed promising results in atopic dermatitis, sending...
Beyond the Lectures: How Conferences Boost Medical Businesses
Conferences are emerging as critical growth engines for medical businesses, offering intensive networking, brand visibility, and real‑time market intelligence. Attending just three well‑chosen events annually can expand a provider’s contact list by roughly 30 % and boost referral rates. The global...
AI Health Support to Be Rolled Out Across Warrington GP Surgeries to Help 55,000 Patients
Warrington Innovation Network’s Primary Care Network is deploying Aide Health’s AI‑driven platform across six GP surgeries, reaching roughly 55,000 patients. The service delivers daily, short‑form check‑ins to help people with COPD, obesity and hypertension manage medication, monitor symptoms and receive...